Proximity Ligation Assay for ER Pathway Activation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the suitability of therapies for cancer patients, particularly those targeting the estrogen receptor (ER) and progesterone receptor (PR) signaling pathways, are inadequate as they cannot determine if the ER pathway is actively engaged in cancer cells, leading to ineffective treatments and resistance mechanisms being overlooked.
Innovation Solution
A method using Proximity Ligation Assay (PLA) to detect the presence of ER and PR family members within transcription factor complexes in tissue samples, allowing for the accurate determination of pathway activation status and potential resistance mechanisms, such as the PI3K pathway, to guide personalized therapy choices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ER staining methods are used to assess therapy suitability, then the procedure is simple and widely applicable, but the measurement precision is insufficient to determine actual pathway activation status
Solution Approach 1:
The patent uses an intermediary molecular complex (ER bound to DNA response elements and co-regulators) as a mediator to detect pathway activation. Instead of directly detecting ER protein presence, the assay detects the formation of this specific molecular complex that serves as an intermediary indicator of active transcriptional signaling, thereby achieving precise pathway activation status determination.
Solution Approach 2:
The patent employs a nested detection strategy where multiple detection layers are combined: first detecting ER protein presence, then detecting its binding to specific DNA response elements, and finally detecting the assembly of co-regulator proteins. This nested approach allows progressive refinement of detection specificity within a unified assay framework.
2Reliability
If single protein staining is performed to assess ER status, then the assay is straightforward and commonly used, but the reliability is insufficient to distinguish between present and actively engaged ER
Solution Approach 1:
The patent segments the ER pathway activation detection into distinct detectable components: ER protein presence, DNA response element binding, and co-regulator recruitment. By segmenting the activation process into these discrete molecular events, the assay can reliably detect which specific components are present and assembled, providing robust prediction of pathway activation status and therapy response.
Solution Approach 2:
The patent utilizes color changes or fluorescent signal changes as visual indicators of pathway activation. The assay employs labeled antibodies or probes that produce detectable color or fluorescence signals when bound to their targets, enabling straightforward visual or instrumental detection of ER pathway activation status without complex measurement procedures.
3Measurement precision
If comprehensive transcription factor complex detection is implemented, then the measurement precision and reliability are improved, but the ease of operation decreases
Solution Approach 1:
The patent merges multiple detection objectives into a single integrated assay procedure. By combining the detection of ER protein, DNA binding, and co-regulator assembly into one unified protocol using a panel of targeted antibodies or probes, the assay achieves comprehensive transcription factor complex detection without requiring separate complex procedures for each detection target.
Solution Approach 2:
The patent employs universal detection reagents such as labeled antibodies that can detect multiple components of the transcription factor complex through a single assay platform. This multi-functional approach allows detection of various proteins and molecular interactions using standardized protocols, maintaining ease of operation while achieving precise complex detection.
Data Source
AI summary
A method for stratification of a patient for assessing suitability of a therapy for the patient suffering from an ER (estrogen receptor) and/or PR (progesterone receptor) positive and HER2 (human epidermal growth factor receptor 2) negative cancer, the therapy being directed towards a signaling pathway, includes: (i) determining an activation status of an ER and/or PR signaling pathway by applying a Proximity Ligation Assay to detect in a tissue sample of the patient a presence of at least one member of the ER family, the at least one member being part of a transcription factor complex, and at least one protein selected from a group consisting of TAFs (TATA-binding protein associated factor), TBP (TATA-box binding protein), POLII (RNA polymerase II), TFII (transcription factor H), p300, CREB (cyclic-AMP response element-binding protein), and CBP (CREB binding protein), wherein the at least one protein is part of the same transcription factor complex.